Population-based comparative survival analysis of surgery with or without adjuvant radiotherapy and non-operative primary radiotherapy in patients with early-stage oral tongue squamous cell carcinoma

Yu Jin Lim*, Moonkyoo Kong

Department of Radiation Oncology, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea

* yujindw@gmail.com

Abstract

Purpose
Although recent clinical guidelines do allow primary radiotherapy for selected patients with early-stage oral tongue cancer, there has been little knowledge on the treatment outcomes of non-operative radiotherapy using modern treatment techniques. This study evaluated recent prognostic differences between primary radiotherapy and surgical resection in T1–2N0 oral tongue squamous cell carcinoma.

Methods
Patients diagnosed with T1–2N0 oral tongue squamous cell carcinoma were identified from the Surveillance, Epidemiology, and End Results database. After propensity score matching, the disease-specific survival of primary radiotherapy and surgery was compared.

Results
From a total of 8,458 patients initially identified, we defined matched cohorts: cohort A, comparing surgery alone vs. primary radiotherapy (n = 230 vs. 230), and cohort B, comparing surgery plus adjuvant radiotherapy vs. primary radiotherapy (n = 230 vs. 230). The 7-year disease-specific survival rates were 77% vs. 35% (cohort A) and 65% vs. 35% (cohort B) (P < 0.001 for all comparisons). Primary radiotherapy was independently associated with worse disease-specific survival in both cohorts A (hazard ratio 4.06; 95% confidence interval 2.53–6.52) and B (hazard ratio 2.81; 95% confidence interval 1.96–4.04). Time-course hazard rate function plots showed a distinct short-term risk increment in disease-specific mortality in the primary radiotherapy group.
Conclusion

In the contemporary treatment era, the use of radiotherapy as a definitive treatment resulted in an inferior prognosis in patients with T1–2N0 oral tongue squamous cell carcinoma. The present population-based data suggest that primary radiotherapy cannot be used as an alternative to surgical management and it needs to be avoided as much as possible in early-stage tumors.

Introduction

According to the recent cancer statistics report by the National Center for Health Statistics in the US, the mortality rate from oral tongue cancer has increased by approximately 2% per year, and 17,960 newly diagnosed cases are expected annually [1]. In contrast to locally advanced or metastatic tumors, patients with early-stage oral tongue cancer have a relatively good prognosis [2]. In general, the preferred management for stage I–II tumors is surgical resection with or without cervical lymph node dissection or sentinel node biopsy [3].

In early-stage oral tongue cancer, optimal local control is essential for favorable long-term prognosis [4]. Most patients with T1–2N0 disease are treated with surgical resection with or without postoperative radiotherapy (RT) according to pathologic adverse features, such as close or positive margins, perineural invasion, vascular invasion, and lymphatic invasion. However, recent clinical guideline does allow primary RT as a therapeutic option in early-stage oral cavity cancers [5]. The use of primary RT has been recommended as an alternative choice for selected patients who are not considered for surgery due to old age, medical comorbidities, or concerns about functional or cosmetic outcomes [6].

Nevertheless, no randomized data are available to compare surgical resection and primary RT in these node-negative early-stage oral cavity cancers. To date, only a few retrospective studies have reported data under contemporary RT planning methods [7–9]. Regarding technical advances over the last several decades, it has been expected that highly conformal RT would lead chances to expand the use of irradiation in clinics [10]. Therefore, it is necessary to evaluate the prognostic outcomes of primary RT in comparison with conventional surgical approaches in real-world practice.

We hypothesized that the long-term disease-specific survival of primary RT over recent years would be inferior to those of surgical resection in early-stage oral tongue squamous cell carcinoma. Based on a large-scale population-based database, this study evaluated the prognostic impact of primary RT using propensity score-matched comparative survival analyses. Since the postoperative risk related to treatment failure is not uniform among the patients treated with surgery, we defined two matched comparison sets: surgery alone vs. primary RT and surgery plus adjuvant RT vs. primary RT. This study provided an additional understanding of whether the use of RT is an alternative definitive management protocol in the contemporary treatment era.

Materials and methods

Study population

We obtained permission to access the Surveillance, Epidemiology and End Results (SEER) 18 database after signing the SEER Research Data Agreement [11]. The SEER database currently covers approximately 35% of the United States population and comprises data from patients...
with cancer from 18 geographical registries [12, 13]. Personal information of registered patients was not included in the database and individual records were identified by assigning patient numbers. As this was a retrospective study of the data, the requirement for obtaining informed consent from patients was waived. Data extraction and manipulation procedures were in accordance with official guidelines [14].

The raw data, including baseline characteristics and overall and cause-specific mortality information, were extracted using the case listing session of SEER+Stat software (version 8.3.6; National Institutes of Health, Bethesda, MD, USA) [15]. The “Site recode ICD-O-3/WHO 2008” variable was used to obtain cases with “tongue” as the primary tumor site. Squamous cell carcinoma was identified based on the third revision of the International Classification of Diseases for Oncology (ICD-O-3), with confirmed positive malignant histology codes. The eligibility criteria included patients with 1) pathologically diagnosed oral tongue squamous cell carcinoma; 2) year of diagnosis between 2004 and 2015; 3) age >18 years; 4) no distant metastasis; 5) early stage with T1–2N0; 6) known information of extent of disease; and 7) cancer-directed local treatment with surgery (with or without adjuvant RT) or primary RT. Fig 1 shows the patient selection process flowchart.

**Propensity score matching**

The cancer-directed local treatment was classified as surgery alone, surgery plus adjuvant RT, and primary RT. To estimate patient survival outcomes of primary RT in comparison with surgical resection, two propensity-matched comparison sets were defined: 1) surgery alone vs. primary RT (cohort A) and 2) surgery plus adjuvant RT vs. primary RT (cohort B). The propensity score is defined as the probability of being assigned to a treatment group [16]. Clinicopathological covariates available in the database were used for propensity-adjusted calculation and matched comparisons. Propensity scores were calculated with a non-parsimonious logistic regression model, and a one-to-one matching process was conducted based on the nearest-neighbor method without replacement. The final propensity-matched comparison set where the standardized difference (SD) values decreased for overall covariates was finally selected for survival analyses (acceptable if SD < 0.1) [17].

**Statistical analysis**

The distribution of baseline variables was compared using the Pearson’s chi-square test and paired t-test or Mann–Whitney U test for continuous and categorical variables, respectively. The primary outcome of interest was disease-specific survival (DSS). Overall survival (OS) and DSS were defined as the interval between the initial date of diagnosis and all-cause and tongue cancer-related death events, respectively. DSS was calculated for patients who were diagnosed with tongue cancer as the first malignancy. Survival outcomes were compared according to different local treatments based on Kaplan-Meier analysis with a log-rank test. After adjustment for potentially related covariates, multivariate analysis for independent prognostic factors was performed using the Cox proportional hazards model. Receiver operating characteristic (ROC) analysis was performed to evaluate the predictive ability of selected variables significantly associated with DSS. The area under the curve (AUC) and 95% confidence interval (CI) were calculated to estimate predictive accuracy. DeLong’s test was used to compare two ROC curves for different variables. The baseline hazard rate function plots for disease-specific mortality events were established using the R package “muhaz.” Two-sided P-values less than 0.05 were considered statistically significant. All statistical analyses were conducted using IBM SPSS Statistics 18 (IBM Corp., Armonk, NY, USA) and R version 4.0.2 (R Foundation for Statistical Computing, Vienna, Austria).
18544 patients diagnosed with oral tongue cancer between 2004 and 2015

↓

17774 patients aged >18 years with pathological diagnosis of squamous cell carcinoma

↓

16650 patients without distant metastasis at diagnosis

↓

9705 patients with T1–2N0 stage

↓

8798 patients with localized disease (known EOD codes information)

↓

8458 patients who underwent surgery or primary radiotherapy as cancer-directed local treatment

Surgery alone (n = 6984)  Surgery + adjuvant RT (n = 1244)  Primary RT (n = 230)

Matched comparisons

Fig 1. Patient selection process flowchart. RT: radiotherapy.
https://doi.org/10.1371/journal.pone.0259384.g001
Results

Initial study population

Initially, we identified 8,458 patients from the SEER database who met the eligibility criteria. S1 Table shows patient baseline characteristics. The median age was 63 years (range, 19–105 years). Most of the patients were Caucasian (87%) with a male predominance (55%). Tumor grade II (48%) was the most common tumor type, followed by grade I (30%) and III–IV (11%). The proportion of T1 tumors (75%) was greater than that of T2 tumors (25%). Tumor size information was available for 89.5% of the patients, with a median value of 1.5 cm (range, 0.1–4.0). The primary tumor subsite was mostly specified at the border (25%) and anterior 2/3 (24%) of the tongue, followed by ventral (16%) and dorsal (5%) surfaces. In 42% of cases, the tumor was located on one side confined to the lamina propria or submucosa, while 23% of tumors extended into the musculature, intrinsic or not otherwise specified. In total, 6,984 (82%), 1,244 (15%), and 230 (3%) patients underwent surgery alone, surgery plus adjuvant RT, and primary RT, respectively. Approximately 91% of the patients in the primary RT group were treated with external beam radiotherapy (EBRT) alone, followed by EBRT combined with brachytherapy (6%) and brachytherapy alone (3%). Fig 2 illustrates the proportion of primary RT methods over time. The proportion of patients undergoing chemotherapy was 1% in the surgery alone group, 19% in the surgery plus adjuvant RT group, and 45% in the primary RT group.

Propensity score-matched cohorts

Applying the propensity score-adjusted calculation, two matched cohorts were established: cohort A, comparing surgery alone vs. primary RT (n = 230 vs. 230), and cohort B, comparing surgery plus adjuvant RT vs. primary RT (n = 230 vs. 230) (S1 Fig). Table 1 shows the distribution of baseline characteristics after propensity score matching. Demographic and clinico-pathological variables (age, sex, race, marital status, tumor grade, T stage, site of primary tumor, and extent of disease) available in the SEER database were analyzed. Regarding different clinical settings in terms of the use of chemotherapy with surgery or primary RT, the
receipt of chemotherapy was not considered in the propensity score matching process; however, it was included as a covariate in the multivariate Cox regression model. Given the matching model, the SD values of all covariates were less than 0.1 in the matched cohorts A and B.

Survival comparisons between the surgery and primary RT groups
In matched cohort A, the 5-year and 7-year OS rates in the surgery alone vs. primary RT were 62% vs. 23% and 53% vs. 17%, respectively, and the DSS rates were 78% vs. 40% and 77% vs.

Table 1. Distribution of variables in the matched cohorts A (surgery alone vs. primary RT) and B (surgery plus adjuvant RT vs primary RT).

| Characteristics       | Matched cohort A [n (%)] | Standardized difference | Matched cohort B [n (%)] | Standardized difference |
|-----------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                       | Surgery (n = 230) | Primary RT (n = 230) | Surgery + adj RT (n = 230) | Primary RT (n = 230) |
| Age (years)           | Mean ± SD              |                          |                          |                          |
|                       | 69.8 ± 12.9            | 69.3 ± 15.2              | 68.8 ± 13.1              | 69.3 ± 15.2              |
| Sex                   |                          |                          |                          |                          |
| Female                | 97 (42)                 | 95 (41)                  | 93 (40)                  | 95 (41)                  |
| Male                  | 133 (58)                | 135 (59)                 | 137 (60)                 | 135 (59)                 |
| Race                  |                          |                          |                          |                          |
| Caucasian             | 193 (84)                | 194 (84)                 | 191 (83)                 | 194 (84)                 |
| Others                | 37 (16)                 | 36 (16)                  | 39 (17)                  | 36 (16)                  |
| Marital status        |                          |                          |                          |                          |
| Married               | 104 (45)                | 100 (44)                 | 100 (44)                 | 100 (44)                 |
| Not married           | 109 (48)                | 115 (50)                 | 116 (50)                 | 115 (50)                 |
| Unknown               | 17 (7)                  | 15 (6)                   | 14 (6)                   | 15 (6)                   |
| Grade                 |                          |                          |                          |                          |
| I                     | 43 (19)                 | 43 (19)                  | 29 (13)                  | 43 (19)                  |
| II                    | 107 (46)                | 104 (45)                 | 123 (53)                 | 104 (45)                 |
| III–IV                | 48 (21)                 | 42 (18)                  | 60 (26)                  | 42 (18)                  |
| Unknown               | 32 (14)                 | 41 (18)                  | 18 (8)                   | 41 (18)                  |
| T stage               |                          |                          |                          |                          |
| T1                    | 74 (32)                 | 70 (30)                  | 76 (33)                  | 70 (30)                  |
| T2                    | 156 (68)                | 160 (70)                 | 154 (67)                 | 160 (70)                 |
| Site of tumor         |                          |                          |                          |                          |
| Dorsal surface        | 15 (7)                  | 18 (8)                   | 14 (6)                   | 18 (8)                   |
| Border                | 43 (19)                 | 51 (22)                  | 43 (19)                  | 51 (22)                  |
| Ventral surface       | 29 (13)                 | 37 (16)                  | 37 (16)                  | 37 (16)                  |
| Anterior 2/3          | 58 (25)                 | 43 (19)                  | 61 (26)                  | 43 (19)                  |
| Overlapping lesion    | 11 (5)                  | 5 (2)                    | 15 (7)                   | 5 (2)                    |
| Not otherwise specified | 74 (32)         | 76 (33)                  | 60 (26)                  | 76 (33)                  |
| Extent of disease     |                          |                          |                          |                          |
| One side confined to lamina propria or submucosa | 29 (12) | 39 (17) | 28 (12) | 39 (17) |
| Musculature, intrinsic or NOS | 28 (12) | 16 (7) | 42 (18) | 16 (7) |
| Localized, NOS        | 61 (27)                 | 67 (29)                  | 50 (22)                  | 67 (29)                  |
| Crosses midline       | 55 (24)                 | 50 (22)                  | 47 (21)                  | 50 (22)                  |
| Invasion to adjacent structures | 57 (25) | 58 (25) | 63 (27) | 58 (25) |

*Base of tongue, lower gingiva, floor of mouth, and sublingual gland were included.
RT: radiotherapy; adj RT: adjuvant RT; SD: standard deviation; NOS: not otherwise specified.

https://doi.org/10.1371/journal.pone.0259384.1001
Comparing surgery plus adjuvant RT vs. primary RT in the matched cohort B, the 5-year and 7-year OS rates were 50% vs. 23% and 42% vs. 17%, respectively, and the DSS rates were 69% vs. 40% and 65% vs. 35%, respectively ($P < 0.001$ for all) (Fig 3C and 3D).

Among the entire study population that was initially identified, the elderly patients aged $\geq 70$ years were additionally selected regarding the median age in the primary RT group. The DSS differences of the old-age patients were statistically significant. The 7-year DSS rates after surgery alone, surgery plus adjuvant RT, and primary RT were 81%, 57%, and 35%, respectively ($P < 0.001$ and $P = 0.001$ for comparisons of surgery alone vs. primary RT and surgery plus adjuvant RT vs. primary RT, respectively) (S2 Fig).

Table 2 shows the results of univariate and multivariate analyses for DSS. In univariate analysis of the matched cohort A, age $> 70$ years (vs. $\leq 70$; $P < 0.001$), T2 stage (vs. T1; $P = 0.009$), tumor size $>$ median 2.7cm (vs. $\leq 2.7$cm; $P = 0.001$), primary RT (vs. surgery alone; $P < 0.001$), and receipt of chemotherapy (vs. no chemotherapy; $P = 0.013$) were associated with worse outcomes. After adjustment for the related covariates, age $> 70$ years (hazard ratio [HR] 2.12; 95% confidence interval [CI] 1.45–3.11) and primary RT as the local treatment (HR 4.06; 95% CI 2.53–6.52) showed an independently poor prognostic association. In matched cohort B, patients aged $> 70$ years (vs. $\leq 70$ years; $P = 0.011$), tumor size $>$ median 2.7cm (vs. $\leq 2.7$cm; $P = 0.075$), and primary RT (vs. surgery plus adjuvant RT; $P < 0.001$) were associated with worse DSS and older age (HR 1.78; 95% CI 1.26–2.53) and use of primary RT (HR 2.81; 95% CI 1.96–4.04) remained significant in the multivariate analysis.
Table 2. Prognostic factors associated with disease-specific survival in matched cohorts A (surgery alone vs. primary RT) and B (surgery plus adjuvant RT vs. primary RT).

| Variables                              | Cohort A          | Cohort B          |
|----------------------------------------|-------------------|-------------------|
|                                        | Univariate        | Multivariate      | Univariate        | Multivariate      |
|                                        | 7-year rate (%)   | P                 | HR [95% CI]       | P                 | 7-year rate (%)   | P                 | HR [95% CI]       | P                 |
| Age (years)                            |                   |                   |                   |                   |
| ≤ 70                                   | 62                | < 0.001           | Ref               | 52                | 0.011             | Ref               |                   |                   |
| > 70                                   | 47                | 2.12 [1.45–3.11]  | < 0.001           | 49                | 1.78 [1.26–2.53]  | 0.001             |                   |                   |
| Sex                                    |                   |                   |                   |                   |
| Female                                 | 52                | 0.218             | 50                | 0.185             |                   |                   |                   |                   |
| Male                                   | 58                |                   | 51                |                   |                   |                   |                   |                   |
| Race                                   |                   |                   |                   |                   |
| Caucasian                              | 56                | 0.743             | 51                | 0.389             |                   |                   |                   |                   |
| Other                                  | 56                |                   | 47                |                   |                   |                   |                   |                   |
| Marital status¹                         |                   |                   |                   |                   |
| Married                                | 58                | 0.415             | 48                | 0.466             |                   |                   |                   |                   |
| Not married                            | 52                |                   | 51                |                   |                   |                   |                   |                   |
| Tumor grade                            |                   |                   |                   |                   |
| I                                      | 57                | 0.370             | 49                | 0.537             |                   |                   |                   |                   |
| II                                     | 52                |                   | 55                |                   |                   |                   |                   |                   |
| III–IV                                 | 64                |                   | 56                |                   |                   |                   |                   |                   |
| T stage                                |                   |                   |                   |                   |
| T1                                     | 65                | 0.009             | Ref               | 58                | 0.123             |                   |                   |                   |
| T2                                     | 51                | 1.48 [0.81–2.71]  | 0.203             | 47                |                   |                   |                   |                   |
| Tumor size (cm)                        |                   |                   |                   |                   |
| ≤ 2.5                                  | 66                | 0.001             | Ref               | 57                | 0.075             | Ref               |                   |                   |
| > 2.5                                  | 47                | 1.39 [0.83–2.31]  | 0.210             | 46                | 1.32 [0.93–1.87]  | 0.117             |                   |                   |
| Local therapy (cohort A)               |                   |                   |                   |                   |
| Surgery alone                          | 77                | < 0.001           | Ref               |                   |                   |                   |                   |                   |
| Primary RT                             | 35                | 4.06 [2.53–6.52]  | < 0.001           |                   |                   |                   |                   |                   |
| Local therapy (cohort B)               |                   |                   |                   |                   |
| Surgery plus adjuvant RT               | 65                | < 0.001           | Ref               |                   |                   |                   |                   |                   |
| Primary RT                             | 35                | 2.81 [1.96–4.04]  | < 0.001           |                   |                   |                   |                   |                   |
| Site of tumor                          |                   |                   |                   |                   |
| Dorsal surface                         | 48                | 0.291             | 42                | 0.693             |                   |                   |                   |                   |
| Border                                 | 48                |                   | 55                |                   |                   |                   |                   |                   |
| Ventral surface                        | 69                |                   | 61                |                   |                   |                   |                   |                   |
| Anterior 2/3                           | 55                |                   | 54                |                   |                   |                   |                   |                   |
| Overlapping lesion                     | 76                |                   | 65                |                   |                   |                   |                   |                   |
| Extent of disease                      |                   |                   |                   |                   |
| One side confined to lamina propria or submucosa | 64 | 0.207             | 51                | 0.169             |                   |                   |                   |                   |
| Musculature, intrinsic or NOS          | 63                |                   | 58                |                   |                   |                   |                   |                   |
| Crosses midline                        | 55                |                   | 57                |                   |                   |                   |                   |                   |
| Invasion to adjacent structures⁰       | 44                |                   | 43                |                   |                   |                   |                   |                   |
| Chemo therapy                          |                   |                   |                   |                   |
| No                                     | 60                | 0.013             | Ref               | 53                | 0.661             |                   |                   |                   |
| Yes                                    | 41                | 0.74 [0.47–1.16]  | 0.187             | 46                |                   |                   |                   |                   |

Base of tongue, lower gingiva, floor of mouth, and sublingual gland were included.
RT: radiotherapy; HR: hazard ratio; CI: confidence interval; Ref: reference; NOS: not otherwise specified.

https://doi.org/10.1371/journal.pone.0259384.t002
Comparison of risk factors with ROC curves

Based on the results of multivariate analyses, prognostic strength of age (> 70 vs. ≤ 70 years) and local treatment (primary RT vs. surgery alone or plus adjuvant RT) were compared using the ROC curves for disease-specific mortality (S3 Fig). In matched cohort A, the AUC values of age (> 70 vs. ≤ 70 years) and local treatment (primary RT vs. surgery alone) were 0.57 (95% CI 0.52–0.63; \( P = 0.153 \)) and 0.68 (95% CI 0.63–0.73; \( P < 0.001 \)), respectively. When the two ROC curves were compared, the difference in prognostic strength was statistically significant (\( P = 0.009 \)). Comparing the curves in the matched cohort B, the difference was also significant (\( P = 0.011 \)), with AUC values of 0.54 (95% CI 0.49–0.59; \( P = 0.442 \)) and 0.64 (95% CI 0.59–0.69; \( P = 0.032 \)) for age (> 70 vs. ≤ 70 years) and local treatment (primary RT vs. surgery plus adjuvant RT), respectively.

Time-course risk changes in disease-specific mortality

The time-course hazard rate function plots for disease-specific mortality are shown in Fig 4. Patients who underwent primary RT showed a short-term risk increment within 3 years of RT, which was distinguishable from the other groups undergoing surgery. In the surgery alone group, there was a sustained lower risk level over the long-term follow-up period. In cases of surgery plus adjuvant RT or primary RT, a trend in increased disease-specific mortality occurring after approximately 8–10 years of follow-up was observed.

Discussion

This study used population-based long-term survival data to evaluate the prognostic impact of primary RT in early-stage T1–2N0 oral tongue squamous cell carcinoma. In propensity-matched comparisons, patients who underwent primary RT had significantly worse DSS than those who underwent surgery alone or surgery plus adjuvant RT. The selection of primary RT showed a considerable association with poorer prognosis, even after adjustment for the effects of other covariates. In the time-course hazard rate function plots, the short-term risk surge of the primary RT group was distinguishable from that of the other groups undergoing surgery.

Fig 4. Hazard rate function plots of disease-specific mortality in the matched cohorts A (A) and B (B): surgery alone (blue) vs. primary RT (red) and surgery plus adjuvant RT (blue) vs. primary RT (red), respectively. RT: radiotherapy; adj RT: adjuvant RT.

https://doi.org/10.1371/journal.pone.0259384.g004
Our matched comparison results provide additional insights into different prognoses according to the selection of definitive local treatment.

Patients with early-stage oral tongue cancer are mainly treated with partial glossectomy with or without cervical lymph node dissection or sentinel node biopsy. However, primary RT has been recommended in selected cases [18]. Old age, significant morbidity, and concerns about postoperative function or cosmetic outcomes are major factors to be considered when choosing non-operative RT, which can be inevitably encountered in real-world clinics [6]. The recent National Comprehensive Cancer Network (NCCN) guideline also states that definitive RT can be considered for T1–2N0 oral tongue tumors, at the discretion of the physician [3]. Nevertheless, the limited number of patients undergoing primary RT has made it difficult to assess the potential role of this non-operative strategy in early-stage oral tongue squamous cell carcinoma [19]. To date, no randomized data are available directly relevant to this topic; some research groups have reported retrospective data. Owing to technical advances in modern RT over the last several decades, additional clinical data are required to update this topic.

Most historical survival outcomes following primary RT were based on small-sized institutional studies (Table 3) [20–29]. The prognosis of patients undergoing RT is considered comparable to that of surgical options on the basis of the reported 5-year OS rates, ranging from 60% to 80%, and the 5-year DSS rates, ranging from 75% to 90%. However, it is important to note that the majority of these studies involved patients undergoing brachytherapy alone or a combination with external beam radiotherapy.

### Table 3. Institutional analyses of primary RT for early-stage oral tongue squamous cell carcinoma.

| First author (year) | Institution (country) | No. of patients | Overall stage | Study period | RT modality and total dose (range or median dose) | 5-year OS rates | 5-year DSS rates |
|---------------------|-----------------------|-----------------|---------------|--------------|-------------------------------------------------|----------------|-----------------|
| Leung (1993) [20]   | Queen Elizabeth Hospital (Hong Kong) | 117 | T1–2 N0–3 | 1979 – 1990 | BT alone (58–80 Gy); n = 51 BT (30–70 Gy) + EBRT (10–60 Gy); n = 14 BT alone (50–80 Gy); n = 52 | 1) I: 81% 2) II: 67% | - |
| Lau (1996) [21]     | British Columbia Cancer Agency (Canada) | 27 | T1–3 N0 | 1989 – 1993 | BT alone (median 45.5 Gy) | 66% | 92% |
| Pernot (1996) [22]  | Centre Alexis Vautrin (France) | 565 | T1–3 | 1973 – 1992 | BT alone (66–75 Gy) | 1) T1: 70% 2) T2: 42% | - |
| Fujita (1999) [23]  | Hiroshima University Hospital (Japan) | 207 | T1–2 N0 | 1980 – 1993 | BT alone (65–70 Gy); n = 127 BT (50–60 Gy) + EBRT (30 Gy); n = 80 | 1) T1: 83.4% 2) T2: 67.8% | 1) T1: 90.1% 2) T2: 76.1% |
| Yamazaki (2007) [24]| Osaka University Hospital (Japan) | 648 | T1–3 N0 | 1967 – 1999 | [According to HDR or LDR] BT alone (55–78 Gy); n = 405 BT (39–78 Gy) + EBRT (20–44 Gy); n = 243 | - | 1) T1: 81–86%<sup>b</sup> 2) T2: 75–81%<sup>b</sup> |
| Oota (2006) [25]    | Tokyo Medical and Dental University Hospital (Japan) | 277 | II | 1970 – 1998 | BT alone (70 Gy); n = 232 BT (60 Gy) + EBRT (30–40 Gy); n = 45 | - | 89.5% |
| Guinot (2010) [26]  | Fundación Instituto Valenciano de Oncología (Spain) | 50 | T1–3 | 1999 – 2007 | BT alone (42–49 Gy); n = 17 BT (12–24.5 Gy) + EBRT (40–70 Gy); n = 33 | 70% | - |
| Akiyama (2012) [27] | Osaka University Hospital (Japan) | 51 | T1–2 N0 | 1996 – 2004 | BT alone (54 Gy or 60 Gy) | (3-year)<sup>c</sup> 1) 54 Gy: 82% 2) 60 Gy: 88% | - |
| Matsumoto (2013) [28]| National Kyushu Medical Center and National Kyushu Cancer Center (Japan) | 67 | T1–2 N0 | 1997 – 2007 | BT alone (40–65 Gy); n = 33 BT (40–65 Gy) + EBRT (7.5–37.5 Gy); n = 34 | 88.7% | 92.1% |
| Bansal (2016) [29]  | Post Graduate Institute of Medical Education and Research (India) | 92 | T1–2 N0 | 1999 – 2014 | BT alone (40–52 Gy); n = 62 BT (18–24 Gy) + EBRT (40 Gy); n = 30 | 73.2% | - |

<sup>a</sup>Number of lesions.

<sup>b</sup>Survival outcomes according to HDR, Iridium-192, and Radium-226.

<sup>c</sup>3-year rates.

RT: radiotherapy; OS: overall survival; DSS: disease-specific survival; BT: brachytherapy; EBRT: external beam radiotherapy; HDR: high-dose rate; LDR: low-dose rate.

https://doi.org/10.1371/journal.pone.0259384.t003
combined brachytherapy with EBRT, that is, not EBRT alone. On the basis of large-scale data, Rusthoven et al. first examined the results of the SEER analyses for stage I–II oral tongue squamous cell carcinoma undergoing definitive RT between 1988 and 2004 [19]. The 5-year OS and DSS rates were reported as 60.9% and 83.5%, respectively, and different local treatment modalities among the patients were not considered. To our knowledge, few studies have addressed whether prognostic data mainly based on EBRT alone are comparable to surgical management in early-stage oral tongue squamous cell carcinoma.

In this study of T1–2N0 cases of oral tongue squamous cell carcinoma diagnosed between 2004 and 2015, only 9% of patients with primary RT were treated with radioisotopes. That is, definitive RT mostly comprising EBRT alone (91%) showed survival outcomes significantly inferior to those derived from previously reported small-sized studies listed in Table 3 [20–29]. The historical favorable outcomes determined in these studies were not based on the use of EBRT alone; therefore, it is not clear whether primary RT solely with the EBRT technique can be clinically recommended. The small proportion of cases of brachytherapy in our data would be related to the widespread use of advanced conformal EBRT techniques [30, 31]. Given the highly conformal irradiation methods used in clinics [32], such as intensity-modulated RT, volumetric modulated arc therapy, and Tomotherapy, the preference for EBRT has increased over the past few decades. Orton et al. used the SEER database to evaluate trends in the use of primary RT modalities in cancer of the oral cavity and found that the rate of brachytherapy use continuously decreased by 0.58% per year \((P < 0.001)\) [33]. Regarding the inferior outcome of primary RT from the population-based data, optimizing the use of RT modalities is necessary to enhance the therapeutic efficacy of definitive RT in patients for whom surgical resection is not medically recommended. Moreover, physicians need to recognize that the selection of primary RT may be an inferior treatment option with worse DSS than expected in early-stage oral tongue squamous cell carcinoma.

Our results derived from hazard rate function plots show that superior treatment efficacy within the initial years of follow-up is necessary to improve prognosis. With regard to short-term tumor control after definitive local treatment, we suggest that site-specific characteristics of oral tongue squamous cell carcinoma should be considered [19]. Since the oral tongue is movable within the oral cavity, early-stage oral tongue cancer lesions can be easily exposed through the mouth, which makes en bloc resection easier than in other head and neck subsites [34]. On the contrary, the accuracy of fixation or localization of the primary tumor site may be a concern in definitive RT [35]. The quality of radiation dose delivery with the EBRT technique may not be uniform across different institutions, but the variability in radiation dose delivery is not a significant issue with interstitial implant. Given the direct contact of radioisotopes with the tumor tissues, brachytherapy allows the maximum dose prescription for gross tumors with a rapid dose fall-off sparing adjacent organs at risk [36], suggesting that better local control is achievable with the use of radioisotopes [20]. Additional outcome analyses directly comparing the EBRT technique and brachytherapy are needed to confirm this hypothesis.

This study has several limitations. Propensity score matching was conducted to minimize the selection bias between different treatment groups; however, other potential bias from unknown covariates, such as performance status and general medical condition, still remains. Nonetheless, the registry includes more recent tumor, patient-related, and outcome records, and disease-specific mortality data were mainly analyzed as the primary outcome of interest to exclude death events irrelevant to tongue cancer diagnosis. Although this study alone cannot establish high-level evidence, we suggest that this hypothesis-generating study also provides useful insights with clinical implications. The predictive power of two prognostic factors for DSS was not sufficiently high in the ROC analyses, which might be attributable to methodological differences. The possible events of side effects and second primary tumors need to be
assessed with respect to the therapeutic index of each treatment; however, the information was not available in the database. The lack of tumor recurrence data was an additional limitation.

In conclusion, this population-based study ascertained that primary RT, mainly based on EBRT alone, resulted in inferior survival outcomes compared to surgical management in patients with early-stage T1-2N0 oral tongue squamous cell carcinoma. In the multivariate analyses of DSS, the selection of primary RT was independently and strongly associated with a worse prognosis. Regarding the critical role of surgical resection as the initial definitive treatment for oral tongue squamous cell carcinoma, it is important to emphasize the inferior long-term outcomes under the contemporary use of RT. To enhance the therapeutic efficacy of RT as a local primary treatment for early-stage oral tongue cancer, the optimal radiation modalities to achieve a curative role should be established. Further prospective investigations are required to validate our results.

Supporting information

S1 Fig. Definition of matched cohorts A and B. RT: radiotherapy; adj RT: adjuvant RT. (TIF)

S2 Fig. Disease-specific survival curves of elderly patients aged ≥70 years when comparing surgery alone vs. primary RT (A) and surgery plus adjuvant RT vs. primary RT (B). RT: radiotherapy; adj RT: adjuvant radiotherapy. (TIF)

S3 Fig. Receiver operator characteristic curves of disease-specific mortality in the matched cohorts A (A) and B (B) comparing age (red) and local treatment (blue). ROC: receiver operator characteristic; Tx: treatment; RT: radiotherapy; adj RT: adjuvant RT. (TIF)

S1 Table. Clinicopathological characteristics of the initially identified study population with T1–2N0 oral tongue squamous cell carcinoma (N = 8458). (DOCX)

Author Contributions

Conceptualization: Yu Jin Lim, Moonkyoo Kong.
Data curation: Yu Jin Lim.
Formal analysis: Yu Jin Lim.
Funding acquisition: Yu Jin Lim.
Investigation: Yu Jin Lim.
Methodology: Yu Jin Lim, Moonkyoo Kong.
Project administration: Yu Jin Lim.
Resources: Yu Jin Lim.
Software: Yu Jin Lim.
Supervision: Moonkyoo Kong.
Validation: Moonkyoo Kong.
Visualization: Yu Jin Lim.
Writing – original draft: Yu Jin Lim.
Writing – review & editing: Yu Jin Lim, Moonkyoo Kong.

References
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71: 7–33. https://doi.org/10.3322/caac.21654 PMID: 33433946
2. Ganly I, Goldstein D, Carlson DL, Patel SG, O’Sullivan B, Lee N, et al. Long-term regional control and survival in patients with “low-risk,” early stage oral tongue cancer managed by partial glossectomy and neck dissection without postoperative radiation: the importance of tumor thickness. Cancer. 2013; 119: 1168–76. https://doi.org/10.1002/cncr.27872 PMID: 23184439
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology—Head and Neck Cancers (Version 1.2021). 2021. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf
4. Sinha N, Rigby MH, McNeil ML, Taylor SM, Trites JR, Hart RD, et al. The histologic risk model is a useful and inexpensive tool to assess risk of recurrence and death in stage I or II squamous cell carcinoma of tongue and floor of mouth. Mod Pathol. 2018; 31: 772–9. https://doi.org/10.1038/modpathol.2017.183 PMID: 29393297
5. Huang SH O’Sullivan B. Oral cancer: Current role of radiotherapy and chemotherapy. Med Oral Patol Oral Cir Bucal. 2013; 18: e233–40. https://doi.org/10.4317/medoral.18772 PMID: 23385513
6. Cabrera-Rodriguez JJ. The role of radiotherapy in the treatment of oral cavity cancer. Plast Aesthet Res. 2016; 3: 158–66. https://doi.org/10.20517/2347-9264.2016.13
7. Ellis MA, Graboyes EM, Wahliquist AE, Nesqy DM, Kaczmar JM, Schopper HK, et al. Primary Surgery vs Radiotherapy for Early Stage Oral Cavity Cancer. Otolaryngol Head Neck Surg. 2018; 158: 649–59. https://doi.org/10.1177/0194599817746909 PMID: 29256326
8. Liu WC, Liu HE, Kao YW, Qin L, Lin KC, Fang CY, et al. Definitive radiotherapy or surgery for early oral squamous cell carcinoma in old and very old patients: A propensity-score-matched, nationwide, population-based cohort study. Radiother Oncol. 2020; 151: 214–21. https://doi.org/10.1016/j.radonc.2020.08.016 PMID: 32866564
9. Liu WC, Liu HE, Kao YW, Qin L, Lin KC, Fang CY, et al. Definitive intensity-modulated radiotherapy or surgery for early oral cavity squamous cell carcinoma: Propensity-score-matched, nationwide, population-based cohort study. Head Neck. 2021; 43: 1142–52. https://doi.org/10.1002/hed.26575 PMID: 33314548
10. Thorwarth D, Muren L. Imaging science and development in modern high-precision radiotherapy. Phys Imaging Radiat Oncol. 2019; 12: 63–6. https://doi.org/10.1016/j.phro.2019.11.008 PMID: 33458297
11. National Cancer Institute. Sample SEER Research Data Use Agreement. 2021. Available from: https://seer.cancer.gov/data/sample-dua.html
12. National Cancer Institute. Overview of the SEER Program. 2021. Available from: https://seer.cancer.gov/about/overview.html
13. National Cancer Institute. Registry Groupings in SEER Data and Statistics. 2021. Available from: https://seer.cancer.gov/registries/terms.html
14. National Cancer Institute. Documentation for SEER Data. 2021. Available from: https://seer.cancer.gov/data-software/documentation/
15. National Cancer Institute. SEER*Stat Software. 2021. Available from: https://seer.cancer.gov/seerstat/
16. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011; 46: 399–424. https://doi.org/10.1080/00273171.2011.568786 PMID: 21818162
17. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 2007; 26: 734–53. https://doi.org/10.1002/sim.2580 PMID: 16708349
18. Hosni A, Chiu K, Huang SH, Xu W, Huang J, Bayley A, et al. Non-operative management for oral cavity carcinoma: Definitive radiation therapy as a potential alternative treatment approach. Radiother Oncol. 2021; 154: 70–5. https://doi.org/10.1016/j.radonc.2020.08.013 PMID: 32961702
19. Rusthoven K, Ballonoff A, Raben D, Chen C. Poor prognosis in patients with stage I and II oral tongue squamous cell carcinoma. Cancer. 2008; 112: 345–51. https://doi.org/10.1002/cncr.23183 PMID: 18041071
20. Leung TW, Lee AW, Chan DK. Definitive radiotherapy for carcinoma of the oral tongue. Acta Oncol. 1993; 32: 559–64. https://doi.org/10.3109/02841869309096118 PMID: 8217241
21. Lau HY, Hay JH, Flores AD, Threlfall WJ. Seven fractions of twice daily high dose-rate brachytherapy for node-negative carcinoma of the mobile tongue results in loss of therapeutic ratio. Radiother Oncol. 1996; 39: 15–8. https://doi.org/10.1016/0167-8140(95)01686-4 PMID: 8735489

22. Pernot M, Hoffstetter S, Peffert D, Aletti P, Lapereyre M, Marchal C, et al. Role of interstitial brachytherapy in oral and oropharyngeal carcinoma: reflection of a series of 1344 patients treated at the time of initial presentation. Otolararyngol Head Neck Surg. 1996; 115: 519–26. https://doi.org/10.1016/s0194-5998(96)70006-2 PMID: 8969757

23. Fujita M, Hirokawa Y, Kashiwado K, Akagi Y, Kashimoto K, Kiriu H, et al. Interstitial brachytherapy for stage I and II squamous cell carcinoma of the oral tongue: factors influencing local control and soft tissue complications. Int J Radiat Oncol Biol Phys. 1999; 44: 767–75. https://doi.org/10.1016/s0360-3016(99)00068-1 PMID: 10386633

24. Yamazaki H, Inoue T, Yoshida K, Yoshioka Y, Furukawa S, Kakimoto N, et al. Comparison of three major radioactive sources for brachytherapy used in the treatment of node negative T1-T3 oral tongue cancer: influence of age on outcome. Anticancer Res. 2007; 27: 491–7. PMID: 17348432

25. Oota S, Shibuya H, Yoshimura R, Watanabe H, Miura M. Brachytherapy of stage II mobile tongue carcinoma. Prediction of local control and QOL. Radiat Oncol. 2006; 1: 21. https://doi.org/10.1186/1748-717X-1-21 PMID: 16834784

26. Guinot JL, Santos M, Tortajada MI, Carrascosa M, Estellés E, Vendrell JB, et al. Efficacy of high-dose-rate interstitial brachytherapy in patients with oral tongue carcinoma. Brachytherapy. 2010; 9: 227–34. https://doi.org/10.1016/j.brachy.2009.10.003 PMID: 20116340

27. Akiyama H, Yoshida K, Shimizu K, Yamazaki H, Koizumi M, Yoshioka Y, et al. Dose reduction trial from 60 Gy in 10 fractions to 54 Gy in 9 fractions schedule in high-dose-rate interstitial brachytherapy for early oral tongue cancer. J Radiat Res. 2012; 53: 722–6. https://doi.org/10.1093/jrr/rrs027 PMID: 22843365

28. Matsumoto K, Sasaki T, Shioyama Y, Nakamura K, Atsumi K, Nonoshita T, et al. Treatment outcome of high-dose-rate interstitial radiation therapy for patients with stage I and II mobile tongue cancer. Jpn J Clin Oncol. 2013; 43: 1012–7. https://doi.org/10.1093/jjco/hyt108 PMID: 23906605

29. Bansal A, Goshal S, Oinam AS, Sharma SC, Dhanireddy B, Kapoor R. High-dose-rate interstitial brachytherapy in early stage oral tongue cancer—15 year experience from a tertiary care institute. J Contemp Brachytherapy. 2016; 8: 56–65. https://doi.org/10.5114/jcb.2016.58982 PMID: 26985198

30. Petereit DG, Frank SJ, Viswanathan AN, Erickson B, Nguyen PL, et al. Brachytherapy: where has it gone? J Clin Oncol. 2015; 33: 980–2. https://doi.org/10.1200/JCO.2014.59.8128 PMID: 25667278

31. Han K, Milosevic M, Fyles A, Pintilie M, Viswanathan AN. Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys. 2013; 87: 111–9. https://doi.org/10.1016/j.ijrobp.2013.05.033 PMID: 23949695

32. Gayen S, Kombathula SH, Manna S, Varshney S, Pareek P. Dosimetric comparison of coplanar and non-coplanar volumetric-modulated arc therapy in head and neck cancer treated with radiotherapy. Radiat Oncol J. 2020; 38: 138–47. https://doi.org/10.3857/roj.2020.00143 PMID: 33012157

33. Orton A, Boothe D, Gan M, Monroe MM, Hitchcock YJ, Lloyd S. The "decay" of brachytherapy use in tumors of the oral cavity: A population-based patterns of care and outcomes analysis from 1973 to 2012. Brachytherapy. 2016; 15: 851–8. https://doi.org/10.1016/j.brachy.2016.05.007 PMID: 27364872

34. Maxwell JH, Thompson LD, Brandwein-Gensler MS, Weiss BG, Canis M, Purigina B, et al. Early Oral Tongue Squamous Cell Carcinoma: Sampling of Margins From Tumor Bed and Worse Local Control. JAMA Otolaryngol Head Neck Surg. 2015; 141: 1104–10. https://doi.org/10.1001/jamaoto.2015.1351 PMID: 2625798

35. Huang Y-M, Lee J-C, Chu C-M, Tai H-C, Hou T-C, Chen FY, et al. Three-Dimensional Printed Silicone Bite Blocks for Radiotherapy of Head and Neck Cancer—A Preliminary Study. Applied Sciences. 2020; 10. https://doi.org/10.3390/app10051688

36. Kovács G, Martinez-Monge R, Budrukkar A, Guinot JL, Johansson B, Stmad V, et al. GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update—Improvement by cross sectional imaging based treatment planning and stepping source technology. Radiother Oncol. 2017; 122: 248–54. https://doi.org/10.1016/j.radonc.2016.10.008 PMID: 27889184